Targeting interferon-γ in hyperinflammation: opportunities and challenges.
Nat Rev Rheumatol
; 17(11): 678-691, 2021 11.
Article
en En
| MEDLINE
| ID: mdl-34611329
ABSTRACT
Interferon-γ (IFNγ) is a pleiotropic cytokine with multiple effects on the inflammatory response and on innate and adaptive immunity. Overproduction of IFNγ underlies several, potentially fatal, hyperinflammatory or immune-mediated diseases. Several data from animal models and/or from translational research in patients point to a role of IFNγ in hyperinflammatory diseases, such as primary haemophagocytic lymphohistiocytosis, various forms of secondary haemophagocytic lymphohistiocytosis, including macrophage activation syndrome, and cytokine release syndrome, all of which are often managed by rheumatologists or in consultation with rheumatologists. Given the effects of IFNγ on B cells and T follicular helper cells, a role for IFNγ in systemic lupus erythematosus pathogenesis is emerging. To improve our understanding of the role of IFNγ in human disease, IFNγ-related biomarkers that are relevant for the management of hyperinflammatory diseases are progressively being identified and studied, especially because circulating levels of IFNγ do not always reflect its overproduction in tissue. These biomarkers include STAT1 (specifically the phosphorylated form), neopterin and the chemokine CXCL9. IFNγ-neutralizing agents have shown efficacy in the treatment of primary haemophagocytic lymphohistiocytosis in clinical trials and initial promising results have been obtained in various forms of secondary haemophagocytic lymphohistiocytosis, including macrophage activation syndrome. In clinical practice, there is a growing body of evidence supporting the usefulness of circulating CXCL9 levels as a biomarker reflecting IFNγ production.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Interferón gamma
/
Linfohistiocitosis Hemofagocítica
/
Enfermedades del Sistema Inmune
/
Inflamación
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Nat Rev Rheumatol
Asunto de la revista:
REUMATOLOGIA
Año:
2021
Tipo del documento:
Article